References

1. Faissner S, Plemel JR, Gold R, Yong VW. Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. *Nat Rev Drug Discov.* 2019;18(12):905-922. doi:10.1038/s41573-019-0035-2

2. Newsome SD, Aliotta PJ, Bainbridge J, et al. CME/CNE Article: A framework of care in multiple sclerosis, Part 1: Updated disease classification and disease-modifying therapy use in specific circumstances. *Int J MS Care.* 2016;18(6):314-323. doi:10.7224/1537-2073.2016-051

3. Olek MJ. Multiple sclerosis. *Ann Intern Med.* 2021;174(6):Itc81-Itc96. doi:10.7326/aitc202106150

4. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol.* 2018;17(2):162-173. doi:10.1016/s1474-4422(17)30470-2

5. Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. *Mult Scler.* 2008;14(9):1157-1174. doi:10.1177/1352458508096878

6. Bowen JD. Highly Aggressive Multiple sclerosis. *Continuum (Minneap Minn).* 2019;25(3):689-714. doi:10.1212/con.0000000000000731

7. Rotstein D, Montalban X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. *Nat Rev Neurol.* 2019;15(5):287-300. doi:10.1038/s41582-019-0170-8

8. Gohil K. Pharmaceutical approval update. *PT.* 2015;40:33-35.

9. Kalincik T, Manouchehrinia A, Sobisek L, et al. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. *Brain.* 2017;140:2426-2443. doi:10.1093/brain/awx185

10. Wingerchuk DM, Weinshenker BG. Disease modifying therapies for relapsing multiple sclerosis. *BMJ.* 2016;354:i3518. doi:10.1136/bmj.i3518

11. Rush CA, MacLean HJ, Freedman MS. Aggressive multiple sclerosis: proposed definition and treatment algorithm. *Nat Rev Neurol.* 2015;11:379-389. doi:10.1038/nrneurol.2015.85

12. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology.* 2018;90:777-788. doi:10.1212/wnl.0000000000005347

13. US Food and Drug Administration. FDA approves new drug to treat multiple sclerosis. Published March 29, 2017. Accessed August 5, 2022. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-multiple-sclerosis

14. US Food and Drug Administration. FDA approves new oral drug to treat multiple sclerosis. Published March 26, 2019. Accessed August 5, 2022. https://www.fda.gov/news-events/press-announcements/fda-approves-new-oral-drug-treat-multiple-sclerosis